Massimo Terzolo

List of Publications by Year
in descending order

256	16,916	17405 63	17055 122
papers	citations	h-index	g-index

266	266	266	8043
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology, 2016, 175, G1-G34.	1.9	1,173
2	A Survey on Adrenal Incidentaloma in Italy¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 637-644.	1.8	693
3	Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine, 2012, 366, 2189-2197.	13.9	692
4	Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. New England Journal of Medicine, 2007, 356, 2372-2380.	13.9	679
5	Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. Journal of Endocrinological Investigation, 2006, 29, 298-302.	1.8	604
6	Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma. Cancer, 2009, 115, 243-250.	2.0	597
7	European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology, 2018, 179, G1-G46.	1.9	559
8	AME Position Statement on adrenal incidentaloma. European Journal of Endocrinology, 2011, 164, 851-870.	1.9	435
9	Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3775-3784.	1.8	369
10	Adrenal Incidentaloma: A New Cause of the Metabolic Syndrome?. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 998-1003.	1.8	300
11	Clinically Guided Genetic Screening in a Large Cohort of Italian Patients with Pheochromocytomas and/or Functional or Nonfunctional Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1541-1547.	1.8	284
12	Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 841-849.	1.8	274
13	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncology, The, 2015, 16, 426-435.	5.1	272
14	Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocrine-Related Cancer, 2005, 12, 657-666.	1.6	255
15	Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. European Journal of Endocrinology, 2006, 155, 823-829.	1.9	239
16	Adrenocortical carcinomas and malignant phaeochromocytomas: ESMOâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2020, 31, 1476-1490.	0.6	209
17	Prognostic factors in stage IIIâ€“IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Annals of Oncology, 2015, 26, 2119-2125.	0.6	196
18	Predictors of morbidity and mortality in acromegaly: an Italian survey. European Journal of Endocrinology, 2012, 167, 189-198.	1.9	189

#	Article	IF	Citations
19	Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas). Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1532-1539.	1.8	180
20	Long-Term Follow-Up in Adrenal Incidentalomas: An Italian Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 827-834.	1.8	180
21	Subclinical Cushing's syndrome in adrenal incidentaloma. Clinical Endocrinology, 1998, 48, 89-97.	1.2	174
22	Retrospective Evaluation of the Outcome of Open Versus Laparoscopic Adrenalectomy for Stage I and II Adrenocortical Cancer. European Urology, 2010, 57, 873-878.	0.9	168
23	Plasma Concentrations of o,pâ€²DDD, o,pâ€²DDA, and o,pâ€²DDE as Predictors of Tumor Response to Mitotane in Adrenocortical Carcinoma: Results of a Retrospective ENS@T Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1844-1851.	1.8	160
24	Subclinical Cushing's Syndrome in Adrenal Incidentalomas. Endocrinology and Metabolism Clinics of North America, 2005, 34, 423-439.	1.2	159
25	Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocrine-Related Cancer, 2008, 15, 1043-1053.	1.6	141
26	Merits and pitfalls of mifepristone in Cushing's syndrome. European Journal of Endocrinology, 2009, 160, 1003-1010.	1.9	141
27	Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocrine-Related Cancer, 2010, 17, 445-453.	1.6	138
28	Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. European Journal of Endocrinology, 2012, 166, 451-458.	1.9	132
29	Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5Î±-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 161-171.	1.8	131
30	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology,the, 2020, 8, 773-781.	5.5	129
31	Prevalence of Adrenal Carcinoma Among Incidentally Discovered Adrenal Masses. Archives of Surgery, 1997, 132, 914.	2.3	128
32	THERAPY OF ENDOCRINE DISEASE: Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushingâ€™s syndrome: a systematic review and meta-analysis. European Journal of Endocrinology, 2016, 175, R283-R295.	1.9	126
33	Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Cancer, 1998, 83, 2194-2200.	2.0	121
34	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. European Urology, 2014, 65, 832-838.	0.9	121
35	Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. European Journal of Endocrinology, 2013, 169, 263-270.	1.9	118
36	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3231-3244.	1.8	113

#	Article	IF	Citations
37	Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology, 2009, 55, 535-543.	1.6	110
38	The corticotrophin-releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing's syndrome. Clinical Endocrinology, 2003, 58, 718-724.	1.2	109
39	Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1358-1365.	1.8	108
40	Subclinical Cushingâ€™s syndrome: definition and management. Clinical Endocrinology, 2012, 76, 12-18.	1.2	106
41	18-Hydroxycorticosterone, 18-Hydroxycortisol, and 18-Oxocortisol in the Diagnosis of Primary Aldosteronism and Its Subtypes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 881-889.	1.8	105
42	Colonoscopic Screening and Follow-Up in Patients with Acromegaly: A Multicenter Study in Italy. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 84-90.	1.8	104
43	Management of adrenal incidentaloma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 233-243.	2.2	99
44	Adjuvant Therapy in Patients With Adrenocortical Carcinoma: A Position of an International Panel. Journal of Clinical Oncology, 2010, 28, e401-e402.	0.8	95
45	Low-Dose Monitored Mitotane Treatment Achieves the Therapeutic Range with Manageable Side Effects in Patients with Adrenocortical Cancer1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2234-2238.	1.8	90
46	Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing?s syndrome. Osteoporosis International, 2004, 15, 855-861.	1.3	90
47	Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features. Journal of Endocrinological Investigation, 1999, 22, 48-54.	1.8	89
48	Management of adrenal cancer: a 2013 update. Journal of Endocrinological Investigation, 2014, 37, 207-217.	1.8	89
49	Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology, 2001, 57, 176-182.	0.5	87
50	Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. European Journal of Endocrinology, 2005, 153, 307-315.	1.9	86
51	Screening of Cushing's syndrome in adult patients with newly diagnosed diabetes mellitus. Clinical Endocrinology, 2007, 67, 225-229.	1.2	81
52	Adrenocortical Tumors With Myxoid Features: A Distinct Morphologic and Phenotypical Variant Exhibiting Malignant Behavior. American Journal of Surgical Pathology, 2010, 34, 973-983.	2.1	81
53	Comparison of Two Mitotane Starting Dose Regimens in Patients With Advanced Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4759-4767.	1.8	80
54	Low-Dose Monitored Mitotane Treatment Achieves the Therapeutic Range with Manageable Side Effects in Patients with Adrenocortical Cancer. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2234-2238.	1.8	80

#	Article	IF	Citations
55	Subclinical Cushing's Syndrome. Pituitary, 2004, 7, 217-223.	1.6	78
56	Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. Human Pathology, 2013, 44, 822-828.	1.1	76
57	Serum Markers of Bone and Collagen Turnover in Patients with Cushingâ€™s Syndrome and in Subjects with Adrenal Incidentalomas. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3303-3307.	1.8	75
58	The Reticulin Algorithm for Adrenocortical Tumor Diagnosis. American Journal of Surgical Pathology, 2013, 37, 1433-1440.	2.1	75
59	Hyperhomocysteinemia in Patients with Cushingâ€™s Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3745-3751.	1.8	74
60	Screening of Cushing's Syndrome in Outpatients with Type 2 Diabetes: Results of a Prospective Multicentric Study in Italy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3467-3475.	1.8	70
61	Adrenal incidentalomas. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 69-82.	2.2	69
62	Validation of the prognostic role of the "Helsinki Scoreâ€•in 225 cases of adrenocortical carcinoma. Human Pathology, 2017, 62, 1-7.	1.1	69
63	Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e973-e981.	1.8	69
64	Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma. Modern Pathology, 2014, 27, 1246-1254.	2.9	67
65	Prognostic factors in ectopic Cushingâ€™s syndrome due to neuroendocrine tumors: a multicenter study. European Journal of Endocrinology, 2017, 176, 453-461.	1.9	66
66	Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer. Clinical Cancer Research, 2012, 18, 3452-3461.	3.2	64
67	Different patterns of steroid secretion in patients with adrenal incidentaloma.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 740-744.	1.8	62
68	Differential responses of serum and salivary interleukin-6 to acute strenuous exercise. European Journal of Applied Physiology, 2005, 93, 679-686.	1.2	62
69	Acromegaly is associated with increased cancer risk: a survey in Italy. Endocrine-Related Cancer, 2017, 24, 495-504.	1.6	61
70	Evaluation of the effectiveness of midnight serum cortisol in the diagnostic procedures for Cushingâ€™s syndrome. European Journal of Endocrinology, 2005, 153, 803-809.	1.9	59
71	Secondary hypoadrenalism. Pituitary, 2008, 11, 147-154.	1.6	58
72	Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Cancer, 1998, 83, 2194-2200.	2.0	56

#	Article	IF	Citations
73	High Prevalence of Colonic Polyps in Patients With Acromegaly. Archives of Internal Medicine, 1994, 154, 1272.	4.3	55
74	Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status. Clinical Endocrinology, 2003, 58, 725-731.	1.2	55
75	Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 499-508.	5.5	55
76	Biochemical Markers of Bone and Collagen Turnover in Acromegaly or Cushing's Syndrome. Hormone and Metabolic Research, 1994, 26, 234-237.	0.7	53
77	Adjunctive treatment of adrenocortical carcinoma. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 221-226.	1.2	53
78	Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors. Annals of Internal Medicine, 2022, 175, 325-334.	2.0	53
79	Relationship between blood pressure and glucose tolerance in acromegaly. Clinical Endocrinology, 2001, 54, 189-195.	1.2	52
80	Oncocytic Adrenocortical Tumors. American Journal of Surgical Pathology, 2011, 35, 1882-1893.	2.1	52
81	Different patterns of steroid secretion in patients with adrenal incidentaloma. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 740-744.	1.8	52
82	Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE). Journal of Endocrinological Investigation, 2016, 39, 103-121.	1.8	51
83	High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2454-2464.	1.8	51
84	Therapeutic Concentrations of Mitotane (o,pâ€²-DDD) Inhibit Thyrotroph Cell Viability and TSH Expression and Secretion in a Mouse Cell Line Model. Endocrinology, 2010, 151, 2453-2461.	1.4	50
85	MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations. Human Pathology, 2014, 45, 1555-1562.	1.1	50
86	Adrenal Incidentalomaâ€”A Modern Disease with Old Complications. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4869-4871.	1.8	49
87	New perspectives for mitotane treatment of adrenocortical carcinoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101415.	2.2	49
88	Cyclic Cushingâ€™s syndrome due to ectopic ACTH secretion by an adrenal pheochromocytoma. Journal of Endocrinological Investigation, 1994, 17, 869-874.	1.8	48
89	The limited value of the desmopressin test in the diagnostic approach to Cushing's syndrome. Clinical Endocrinology, 2001, 54, 609-616.	1.2	48
90	The Patients with Incidentally Discovered Adrenal Adenoma (Incidentaloma) Are Not at Increased Risk of Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 604-607.	1.8	47

#	Article	IF	Citations
91	Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas. Modern Pathology, 2006, 19, 1563-1569.	2.9	47
92	Effects of High-Intensity Isokinetic Exercise on Salivary Cortisol in Athletes with Different Training Schedules: Relationships to Serum Cortisol and Lactate. International Journal of Sports Medicine, 2005, 26, 747-755.	0.8	46
93	The value of dehydroepiandrosterone sulfate measurement in the differentiation between benign and malignant adrenal masses. European Journal of Endocrinology, 2000, 142, 611-617.	1.9	44
94	MHC2TA Single Nucleotide Polymorphism and Genetic Risk for Autoimmune Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4107-4111.	1.8	44
95	Bilateral adrenalectomy for Cushingâ€™s syndrome: A comparison between laparoscopy and open surgery. Journal of Endocrinological Investigation, 2004, 27, 654-658.	1.8	43
96	Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism. Diabetic Medicine, 2009, 26, 968-973.	1.2	43
97	Subclinical Cushing's syndrome. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 1272-1279.	1.3	41
98	CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. PLoS ONE, 2014, 9, e105855.	1.1	41
99	S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. European Journal of Endocrinology, 2022, 186, 25-36.	1.9	41
100	Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer and Prostatic Diseases, 2009, 12, 94-99.	2.0	38
101	Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. Cancers, 2020, 12, 941.	1.7	38
102	Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. European Journal of Endocrinology, 2019, 180, 387-396.	1.9	38
103	Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer, 1998, 83, 2194-200.	2.0	38
104	GH and IGFâ€‰ excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Clinical Endocrinology, 2008, 69, 613-620.	1.2	37
105	Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. Cancer Treatment Reviews, 2013, 39, 966-973.	3.4	37
106	Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenetics and Genomics, 2013, 23, 293-300.	0.7	37
107	Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System. Frontiers in Endocrinology, 2021, 12, 738848.	1.5	36
108	Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options. Expert Review of Anticancer Therapy, 2018, 18, 1125-1133.	1.1	34

#	Article	IF	Citations
109	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3491-3498.	1.8	33
110	Serum levels of bone GLA protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegly: Effects of long-term octreotide treatment. Calcified Tissue International, 1993, 52, 188-191.	1.5	32
111	Management of adjuvant mitotane therapy following resection of adrenal cancer. Endocrine, 2012, 42, 521-525.	1.1	31
112	Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4594-4602.	1.8	31
113	Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. Journal of Clinical Medicine, 2019, 8, 1850.	1.0	31
114	Effects of Long-Term, Low-Dose, Time-Specified Melatonin Administration on Endocrine and Cardiovascular Variables in Adult Men. Journal of Pineal Research, 1990, 9, 113-124.	3.4	30
115	Laboratory differentiation of Cushing's syndrome. Clinica Chimica Acta, 2008, 388, 5-14.	0.5	30
116	Assessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency. European Journal of Endocrinology, 2012, 167, 769-776.	1.9	30
117	Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. European Journal of Endocrinology, 2019, 181, 681-689.	1.9	30
118	Emerging drugs for adrenocortical carcinoma. Expert Opinion on Emerging Drugs, 2008, 13, 497-509.	1.0	29
119	Practical treatment using mitotane for adrenocortical carcinoma. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 159-165.	1.2	29
120	Adrenocortical Carcinoma with Hypercortisolism. Endocrinology and Metabolism Clinics of North America, 2018, 47, 395-407.	1.2	29
121	Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. Frontiers in Endocrinology, 2021, 12, 662865.	1.5	29
122	A new simple HPLC method for measuring mitotane and its two principal metabolites. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 837, 69-75.	1.2	28
123	Palbociclib inhibits proliferation of human adrenocortical tumor cells. Endocrine, 2018, 59, 213-217.	1.1	28
124	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. Cancers, 2020, 12, 740.	1.7	28
125	Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy. Hypertension Research, 2020, 43, 500-510.	1.5	26
126	24-Hour Profiles of Blood Pressure and Heart Rate in Cushing's Syndrome: Relationship Between Cortisol and Cardiovascular Rhythmicities. Chronobiology International, 1990, 7, 263-265.	0.9	25

#	Article	IF	Citations
127	Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. Molecular and Cellular Endocrinology, 2014, 382, 1-7.	1.6	25
128	Effects of mitotane on the hypothalamicâ€“pituitaryâ€“adrenal axis in patients with adrenocortical carcinoma. European Journal of Endocrinology, 2017, 177, 361-367.	1.9	25
129	Evening administration of melatonin enhances the pulsatile secretion of prolactin but not of LH and TSH in normally cycling women. Clinical Endocrinology, 1993, 39, 185-191.	1.2	24
130	Recurrent thromboembolism as a hallmark of Cushingâ€™s syndrome. Journal of Endocrinological Investigation, 1997, 20, 211-214.	1.8	24
131	Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function. Journal of Endocrinology, 2013, 218, 275-285.	1.2	24
132	Topoisomerase 2Î± and thymidylate synthase expression in adrenocortical cancer. Endocrine-Related Cancer, 2017, 24, 319-327.	1.6	24
133	Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer. Cancers, 2020, 12, 2615.	1.7	24
134	What is the role of ultrasonography in the follow-up of adrenal incidentalomas?. Urology, 1999, 54, 612-616.	0.5	23
135	CYP11B2 â^'344T/C Gene Polymorphism and Blood Pressure in Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 5008-5012.	1.8	23
136	Increased Osteoprotegerin Levels in Cushingâ€™s Syndrome Are Associated with an Adverse Cardiovascular Risk Profile. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1803-1808.	1.8	23
137	Cortisol secretion, bone health, and bone loss: a cross-sectional and prospective study in normal nonosteoporotic women in the early postmenopausal period. European Journal of Endocrinology, 2012, 166, 855-860.	1.9	23
138	RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization. Molecular and Cellular Endocrinology, 2015, 401, 105-110.	1.6	23
139	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. Cancers, 2020, 12, 359.	1.7	23
140	Treatment With 90Y/177Lu-DOTATOC in Patients With Metastatic Adrenocortical Carcinoma Expressing Somatostatin Receptors. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1-e5.	1.8	22
141	Melatonin and human cancer. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37, 983-987.	1.2	21
142	Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivo. International Journal of Cancer, 2018, 143, 199-211.	2.3	21
143	Adding metyrapone to chemotherapy plus mitotane for Cushingâ€™s syndrome due to advanced adrenocortical carcinoma. Endocrine, 2018, 61, 169-172.	1.1	21
144	In vitro antitumor activity of progesterone in human adrenocortical carcinoma. Endocrine, 2019, 63, 592-601.	1.1	21

#	Article	IF	Citations
145	Ketoconazole treatment in Cushingâ€™s disease. Effect on the circadian profile of plasma ACTH and Cortisol. Journal of Endocrinological Investigation, 1988, 11, 717-721.	1.8	20
146	Hypertension and Acromegaly. Endocrinology and Metabolism Clinics of North America, 2019, 48, 779-793.	1.2	20
147	Misdiagnosis of Cushing's Syndrome in a Patient Receiving Rifampicin Therapy for Tuberculosis. Hormone and Metabolic Research, 1995, 27, 148-150.	0.7	18
148	Assessment of functional liver mass and plasma flow in acromegaly before and after long-term treatment with octreotide. Metabolism: Clinical and Experimental, 1996, 45, 109-113.	1.5	18
149	Myxoid adrenocortical adenoma with a pseudoglandular pattern. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 414-418.	1.4	18
150	The combined low-dose dexamethasone suppression corticotropin-releasing hormone test as a tool to rule out Cushing's syndrome. European Journal of Endocrinology, 2008, 159, 569-576.	1.9	18
151	Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2642-2653.	1.8	18
152	Surgical remission of Cushing's syndrome reduces cardiovascular risk. European Journal of Endocrinology, 2014, 171, 127-136.	1.9	17
153	18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma. European Journal of Endocrinology, 2015, 173, 749-756.	1.9	17
154	Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas. Modern Pathology, 2018, 31, 1257-1269.	2.9	17
155	Pros and cons of dexamethasone suppression test for screening of subclinical Cushingâ€™s syndrome in patients with adrenal incidentalomas. Journal of Endocrinological Investigation, 2011, 34, e1-e5.	1.8	16
156	Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma. Cancers, 2020, 12, 639.	1.7	16
157	Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells. Cancers, 2020, 12, 928.	1.7	16
158	Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients. Journal of the Endocrine Society, 2021, 5, A166-A167.	0.1	16
159	Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. European Journal of Endocrinology, 2019, 180, 311-320.	1.9	16
160	Favorable Response of Metastatic Adrenocortical Carcinoma to Etoposide, Adriamycin and Cisplatin (EAP) Chemotherapy. Report of two Cases. Tumori, 1992, 78, 345-348.	0.6	15
161	Adjuvant Mitotane for Adrenocortical Cancerâ€"Working through Uncertainty. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1879-1880.	1.8	15
162	Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma. Endocrine Pathology, 2017, 28, 95-102.	5.2	15

#	Article	IF	Citations
163	Definition of an optimal strategy to evaluate and follow-up adrenal incidentalomas: time for further research. European Journal of Endocrinology, 2009, 161, 529-532.	1.9	14
164	Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. Annals of Oncology, 2011, 22, 988-990.	0.6	14
165	Does nephrectomy during radical adrenalectomy for stage II adrenocortical cancer affect patient outcome?. Journal of Endocrinological Investigation, 2016, 39, 465-471.	1.8	14
166	What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. Journal of Personalized Medicine, 2021, 11, 269.	1.1	14
167	Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study. British Journal of Cancer, 2021, 125, 1233-1238.	2.9	14
168	Metronomic Therapy Concepts in the Management of Adrenocortical Carcinoma. Hormones and Cancer, 2011, 2, 378-384.	4.9	13
169	In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell culturesâ˜†. Molecular and Cellular Endocrinology, 2019, 498, 110585.	1.6	13
170	Analysis of BCLI, N363S and ER22/23EK Polymorphisms of the Glucocorticoid Receptor Gene in Adrenal Incidentalomas. PLoS ONE, 2016, 11, e0162437.	1.1	13
171	Preoperative treatment with metyrapone in patients with Cushingâ€™s syndrome due to adrenal adenoma: a pilot prospective study. Endocrine Connections, 2018, 7, 1227-1235.	0.8	13
172	Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies. Cancers, 2021, 13, 5255.	1.7	13
173	ENDOCRINE TUMOURS: Our experience with the management of patients with non-metastatic adrenocortical carcinoma. European Journal of Endocrinology, 2022, 187, R27-R40.	1.9	13
174	Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane. Journal of Endocrinological Investigation, 2006, 29, 560-562.	1.8	12
175	Circadian profile of serum melatonin in patients with Cushingâ€™s syndrome or acromegaly. Journal of Endocrinological Investigation, 1995, 18, 17-24.	1.8	11
176	Adrenocortical Carcinoma Xenograft in Zebrafish Embryos as a Model To Study the In Vivo Cytotoxicity of Abiraterone Acetate. Endocrinology, 2019, 160, 2620-2629.	1.4	11
177	ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. European Journal of Endocrinology, 2021, 184, R51-R59.	1.9	11
178	High prevalence of colonic polyps in patients with acromegaly. Influence of sex and age. Archives of Internal Medicine, 1994, 154, 1272-1276.	4.3	11
179	Management of Severe Cushing Syndrome Induced by Adrenocortical Carcinoma with Abiraterone Acetate: A Case Report. AACE Clinical Case Reports, 2016, 2, e337-e341.	0.4	11
180	Feasibility of the association of mitotane with etoposide, adriamycin and cisplatin combination chemotherapy in advanced adrenocortical cancer patients. Report on 7 cases. Annals of Oncology, 1995, 6, 509-510.	0.6	10

#	Article	IF	Citations
181	Doppler echocardiographic patterns in patients with acromegaly. Journal of Endocrinological Investigation, 1995, 18, 613-620.	1.8	10
182	Coexistence of unilateral adrenal macronodule and Cushingâ€™s disease. Report of two cases. Journal of Endocrinological Investigation, 1996, 19, 131-135.	1.8	10
183	CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. PLoS ONE, 2018, 13, e0196931.	1.1	10
184	Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation. European Radiology, 2020, 30, 6958-6964.	2.3	10
185	Cushing syndrome due to ectopic adrenocorticotropic hormone secretion in a 3-year-old child. Journal of Pediatric Endocrinology and Metabolism, 2011, 24, 219-22.	0.4	9
186	Autonomous hypercortisolism: definition and clinical implications. Minerva Endocrinologica, 2018, 44, 33-42.	1.7	9
187	Cortical-Sparing Laparoscopic Adrenalectomy in a Patient with Multiple Endocrine Neoplasia Type IIA. Hormone Research in Paediatrics, 2002, 57, 197-199.	0.8	8
188	Management of Adrenal Incidentalomas. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 166-170.	0.6	8
189	Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinomaâ€â€¡. Journal of Pharmacy and Pharmacology, 2017, 69, 1524-1530.	1.2	8
190	Insights on the Natural History of Adrenal Incidentalomas. Annals of Internal Medicine, 2019, 171, 135.	2.0	8
191	Exogenous melatonin enhances the TRH-induced prolactin release in normally cycling women: A sex-specific effect. Gynecological Endocrinology, 1991, 5, 83-94.	0.7	7
192	Evaluation of Midnight Salivary Cortisol as a Predictor Factor for Common Carotid Arteries Intima Media Thickness in Patients with Clinically Inapparent Adrenal Adenomas. International Journal of Endocrinology, 2015, 2015, 1-7.	0.6	7
193	SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas. Journal of the Endocrine Society, 2019, 3, .	0.1	7
194	Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant. Frontiers in Endocrinology, 2021, 12, 793262.	1.5	7
195	Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma. ESMO Open, 2022, 7, 100422.	2.0	7
196	Circadian Profile of Serum Melatonin in Cushing's Disease and Acromegaly. Chronobiology International, 1990, 7, 259-261.	0.9	6
197	Adrenal Incidentalomas and Subclinical Cushingï¿½s Syndrome: Is There Evidence for Glucocorticoid-Induced Osteoporosis?. , 2002, 30, 73-85.		6
198	Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma. Journal of Endocrinological Investigation, 2013, 36, 148-52.	1.8	6

#	Article	IF	Citations
199	Is Follow-up of Adrenal Incidentalomas Always Mandatory?. Endocrinology and Metabolism, 2020, 35, 26.	1.3	6
200	Limited Role of Hair Cortisol and Cortisone Measurement for Detecting Cortisol Autonomy in Patients With Adrenal Incidentalomas. Frontiers in Endocrinology, 2022, 13, 833514.	1.5	6
201	Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases. Tumori, 1992, 78, 345-8.	0.6	6
202	First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.. Journal of Clinical Oncology, 2022, 40, 1-1.	0.8	6
203	Humoral immune response to SARS-CoV-2 in five different groups of individuals at different environmental and professional risk of infection. Scientific Reports, 2021, 11, 24503.	1.6	6
204	Acute administration of melatonin at two opposite circadian stages does not change responses to gonadotropin releasing hormone, thyrotropin releasing hormone and ACTH in healthy adult males. Journal of Endocrinological Investigation, 1987, 10, 471-477.	1.8	5
205	PLASMA steroid responses to circadian-stage-specified injection of different doses of the acth analogue alsactide (ACTH 1â€“17) in healthy adult human males. Research in Clinic and Laboratory, 1988, 18, 95-104.	0.3	5
206	Bone and Collagen Turnover in Patients with Active and Preclinical Cushingâ€™s Syndrome and in Subjects with Adrenal Incidentalomaâ€”Authorsâ€™ Response. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2605-2606.	1.8	5
207	May an Altered Hypothalamoâ€“Pituitaryâ€“Adrenal Axis Contribute to Cortical Bone Damage in Primary Hyperparathyroidism?. Calcified Tissue International, 2009, 84, 425-429.	1.5	5
208	Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment. Endocrine, 2014, 45, 122-127.	1.1	5
209	Dual-Energy X-ray Absorptiometry Predictors of Vertebral Deformities in Beta-Thalassemia Major. Journal of Clinical Densitometry, 2018, 21, 507-516.	0.5	5
210	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. Cancers, 2021, 13, 5831.	1.7	5
211	Effects of exogenous melatonin on human pituitary and adrenal secretions. Hormonal responses to specific stimuli after acute administration of different doses at two opposite circadian stages in men. Chronobiologia, 1988, 15, 279-87.	0.1	5
212	Adrenal incidentaloma, a five year experience. Minerva Endocrinologica, 1995, 20, 69-78.	1.7	5
213	Development and internal validation of a predictive model for the estimation of pheochromocytoma recurrence risk after radical surgery. European Journal of Endocrinology, 2022, 186, 399-406.	1.9	5
214	Morning to evening changes of human pituitary and adrenal responses to specific stimuli. Journal of Endocrinological Investigation, 1990, 13, 181-185.	1.8	4
215	Hyperparathyroidism associated with hyperthyroidism. Journal of Endocrinological Investigation, 1992, 15, 147-148.	1.8	4
216	Effects on bone health of glucocorticoid replacement therapy in primary and secondary adrenal insufficiency: A review. Current Opinion in Endocrine and Metabolic Research, 2018, 3, 31-37.	0.6	4

#	Article	IF	Citations
217	The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2406-2407.	1.8	4
218	Diabetes insipidus associated with empty sella: report of two cases. Journal of Endocrinological Investigation, 1990, 13, 351-352.	1.8	3
219	Desmopressin Test in Mild Cushing Syndrome. Archives of Internal Medicine, 2003, 163, 850.	4.3	3
220	Determination of salivary cortisol to assess time-related changes of the adrenal response to stress in critically ill patients. European Journal of Internal Medicine, 2019, 68, 66-70.	1.0	3
221	What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study. Journal of Endocrinological Investigation, 2021, 44, 865-872.	1.8	3
222	Differential Expression Profiles of Cell-to-Matrix-Related Molecules in Adrenal Cortical Tumors: Diagnostic and Prognostic Implications. Journal of Personalized Medicine, 2021, 11, 378.	1.1	3
223	Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2167-e2176.	1.8	3
224	The neoplastic complications of acromegaly. Journal of Endocrinological Investigation, 2003, 26, 32-4.	1.8	3
225	From SGAP-Model to SGAP-Score: A Simplified Predictive Tool for Post-Surgical Recurrence of Pheochromocytoma. Biomedicines, 2022, 10, 1310.	1.4	3
226	Adrenal Incidentalomas. Growth Hormone, 2000, , 191-211.	0.2	2
227	Progression of renal failure without proteinuria in a patient with type 1 diabetes. Nephrology Dialysis Transplantation, 2004, 19, 3197-3199.	0.4	2
228	A current perspective on treatment of adrenocortical carcinoma. Expert Opinion on Orphan Drugs, 2014, 2, 911-921.	0.5	2
229	Novel mutation of PPOX gene in a patient with abdominal pain and syndrome of inappropriate antidiuresis. Endocrine, 2018, 61, 403-406.	1.1	2
230	Acute Primary Adrenal Insufficiency after Hip Replacement in a Patient with Acute Intermittent Porphyria. Case Reports in Endocrinology, 2018, 2018, 1-4.	0.2	2
231	Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma. Cells, 2020, 9, 885.	1.8	2
232	Multiple rebound-associated vertebral fractures after denosumab discontinuation: is prompt antiresorptive therapy always recommended, even when the risk of fracture seems low? A case report. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, .	0.6	2
233	A Follow-Up Evaluation of Patients with Incidentally Discovered Adrenal Adenoma. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 167.	1.0	2
234	Patients With Lung Cancer and Coronavirus Disease 2019 Epidemic: An Experience From an Italian University Hospital. JTO Clinical and Research Reports, 2020, 1, 100067.	0.6	2

#	Article	IF	Citations
235	Assesment of hepatic functional mass and plasma flow in acromegaly and effects of treatment with a long-active somatostatin analogue. Journal of Hepatology, 1991, 13, S92.	1.8	1
236	Molecular target agents in adrenocortical carcinoma: rationale and difficulties in trial design. International Journal of Endocrine Oncology, 2014, 1, 31-34.	0.4	1
237	Mitotane: new facts for an old drug. Current Opinion in Endocrine and Metabolic Research, 2019, 8, 145-151.	0.6	1
238	May an adrenal incidentaloma change its nature?. Journal of Endocrinological Investigation, 2020, 43, 1301-1307.	1.8	1
239	Modified GRAS Score for Prognostic Classification of Adrenocortical Carcinoma: An ENSAT Multicentre Study. Journal of the Endocrine Society, 2021, 5, A165-A166.	0.1	1
240	Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy. Endocrine, 2021, 72, 20-23.	1.1	1
241	Mitotane Levels Affect the Outcome of Patients Treated Adjuvantly Following Radical Resection of Adrenocortical Cancer (ACC). , 2011, , OR13-2-OR13-2.		1
242	Acromegaly and Gastrointestinal Cancer-Reply. Archives of Internal Medicine, 1995, 155, 213.	4.3	0
243	Rapporto tra acromegalia e neoplasia: fantasia o realtÃ?. L Endocrinologo, 2007, 8, 37-53.	0.0	0
244	End-stage renal failure due to amyloidosis and recurrent fever on dialysis–is there a link?. Nephrology Dialysis Transplantation, 2008, 23, 2419-2421.	0.4	0
245	Adrenal Cortical Carcinoma: Mitotane and Beyond. Contemporary Endocrinology, 2018, , 311-330.	0.3	0
246	Adrenal Incidentalomas. , 2018, , 303-307.		0
247	Adrenocortical Carcinoma: Diagnosis and Therapy. , 2019, , 308-316.		0
248	Adrenal tumours. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101435.	2.2	0
249	Adrenal Hyperplasia as Possible Predictor of Mortality in Patients Admitted for Suspected SARS-Cov-2 Infection: A Prospective Study. Journal of the Endocrine Society, 2021, 5, A76-A76.	0.1	0
250	Adrenocortical Cancer. , 2021, , 319-326.		0
251	Prolactinoma in a Diabetic Dialysis Patient with Erectile Dysfunction: A Difficult Differential Diagnosis. Review of Diabetic Studies, 2006, 3, 200-200.	0.5	0
252	Mitotane. , 2009, , 369-381.		0

#	Article	IF	Citations
253	Adrenal incidentaloma. , 2011, , 781-788.		0
254	Low dehydroepiandrosterone sulfate (DHEA-S) level is not a good predictor of hormonal activity in nonselected patients with incidentally detected tumors. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 4503-4504.	1.8	0
255	OR29-2 Mild Autonomous Cortisol Excess (MACE) in Adrenal Incidentalomas - Metabolic Risk Profile and Urinary Steroid Metabolome Analysis in 1208 Prospectively Recruited Patients. Journal of the Endocrine Society, 2019, 3, .	0.1	0
256	SUN-350 Sterol-O-Acyl Transferase 1 Protein Expression Alone Is Not Sufficient to Predict Response to Mitotane Treatment in Adrenocortical Carcinoma. Journal of the Endocrine Society, 2019, 3, .	0.1	0